Pharmacological inhibition of METTL1 as a therapy against solid and blood cancers
En palabras de los autores
Abstract The N7-methylguanosine (m 7 G) modification is one of the most prevalent tRNA modifications, mainly catalysed by the METTL1–WDR4 protein complex 1–4 . The m 7 G methyltransferase METTL1 has been linked to oncogenic transformation and the maintenance of several aggressive malignancies; however, the clinical implications of therapeutically targeting a tRNA-modifying enzyme have not been established. Here we present the development and characterization of STM9005, a highly selective and potent first-in-class tRNA methyltransferase inhibitor of METTL1. Treatment of numerous cancer cell models (including leukaemia, melanoma, pancreatic carcinoma, oesophageal cancer and small cell lung carcinoma) with STM9005 blocks cell growth, causes differentiation changes and dysregulates cell cycle progression. These cellular effects were accompanied by a selective decrease in m 7 G on a subset of tRNAs and a reduction in their expression levels, which impacted the translation of oncogenic mRNAs. We show that pharmacological inhibition of METTL1 in vivo impairs tumour growth and significantly prolongs survival in multiple mouse cancer models of different tissue origin. Collectively, our results provide a strong proof of concept that targeting of tRNA methylation is a promising avenue of anti-cancer therapy and illustrate that catalytic inhibition of METTL1 represents a therapeutic strategy against a number of aggressive malignancies.
En palabras simples Resumen con IA
Los autores desarrollaron STM9005, un medicamento de primera clase que bloquea METTL1, una enzima que modifica el ARNt. STM9005 detuvo el crecimiento de células cancerosas en modelos de leucemia, melanoma, cáncer de páncreas, esófago y pulmón. El medicamento redujo las marcas de m7G en ARNt específicos, disminuyendo sus niveles y alterando la traducción de ARNm que promueven el cáncer. En ratones, el bloqueo de METTL1 ralentizó el crecimiento tumoral y extendió la supervivencia en varios tipos de cáncer. Los autores concluyen que dirigirse a la metilación del ARNt mediante la inhibición de METTL1 puede ser un enfoque prometedor contra el cáncer.
Escrito por Kimi K2.5 usando solo el abstract de arriba. Jev verificó que cada oración esté respaldada por las oraciones del abstract que cita y eliminó las que no. Pasá el cursor por una oración para ver de dónde sale.
Apareció: viernes, 30 de octubre. Nature. Revista con revisión por pares.